Health Diagnostic Laboratory (HDL) Inc. in Richmond said Wednesday that it is partnering with an Oregon-based biotechnology venture to develop a new test for assessing heart attack and stroke risk.
In the joint effort, Gamma Therapeutics Inc. plans to bring to market a risk assay for cardiovascular disease that would help assess illness by providing a new predictive tool.
Health Diagnostic said in a statement that the assay is based on a naturally occurring clotting protein in human blood called gamma prime fibrinogen, a biomarker strongly associated with cardiovascular disease. The laboratory test version of the assay will be offered exclusively by HDL, which also will take the lead in BETA testing of the assay for approval by the Federal Drug Administration.
“Thanks to advanced testing, it’s now possible to reveal risk factors and biomarkers for cardiovascular and related diseases,” Tonya Mallory, CEO of HDL, said in a statement.